Clobazam

證據等級: L5

預測適應症: 10 個

One-Sentence Summary

Clobazam is a 1,5-benzodiazepine antiepileptic and anxiolytic drug, established in international guidelines as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) and one of only eight ASMs with specific FDA approval for that indication. The TxGNN model predicts it may be effective for Febrile Infection-Related Epilepsy Syndrome (FIRES), a catastrophic super-refractory status epilepticus occurring in previously healthy individuals, with 0 clinical trials and 2 publications (indirect, class-level benzodiazepine evidence) currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Adjunctive therapy for seizures in Lennox-Gastaut syndrome (FDA-approved internationally; not registered in New Zealand)
Predicted New Indication	Febrile Infection-Related Epilepsy Syndrome (FIRES)
TxGNN Prediction Score	99.82%
Evidence Level	L4
New Zealand Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the current evidence pack. Based on published literature, clobazam is a 1,5-benzodiazepine that acts as a positive allosteric modulator (PAM) of GABA-A receptors — enhancing chloride ion influx, augmenting inhibitory neurotransmission, and raising the seizure threshold across multiple seizure types. Unlike classical 1,4-benzodiazepines (diazepam, clonazepam), its 1,5-diazepine ring confers a longer effective half-life (active metabolite N-desmethylclobazam t½ ~71 h), oral bioavailability, and a relatively favourable sedation and tolerance profile, which makes it pharmacokinetically suitable for sub-acute and chronic seizure management.

FIRES is a form of new-onset refractory status epilepticus (NORSE) triggered by a febrile illness, characterised by catastrophic, drug-resistant seizures requiring prolonged pharmacological coma with midazolam, pentobarbital or propofol. The critical clinical challenge is the sub-acute weaning phase: clinicians need a longer-acting oral agent that can substitute for intravenous anaesthetics while maintaining seizure control. The existing literature demonstrates proof-of-concept for oral benzodiazepines in this role — PMID 35770765 (2022) reports successful use of enteral lorazepam as a midazolam-weaning strategy in midazolam-dependent FIRES patients. Clobazam, sharing the same GABA-A PAM mechanism but offering superior duration of action and oral formulation, is a logical next candidate for this weaning role.

Clobazam's strongest established evidence sits within the broader epileptic encephalopathy spectrum. It is included in AAN 2018 practice guidelines (Level A recommendation; PMID 29898971), two Cochrane reviews support its use in focal and generalised seizures (PMID 29995989, PMID 25280512), and a prospective study confirms add-on efficacy in temporal lobe epilepsy with hippocampal sclerosis (PMID 15825553). The TxGNN knowledge graph captures this mechanistic and nosological proximity between LGS-type encephalopathies and FIRES, explaining the high prediction score. However, no current study directly evaluates clobazam in FIRES, leaving the extrapolation at the preclinical / mechanistic reasoning level.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35770765	2022	Case Series	Epileptic Disorders	Enteral lorazepam served as an effective oral benzodiazepine weaning substitute for midazolam in FIRES; provides class-level proof-of-concept that oral BZDs can bridge the sub-acute FIRES phase — the role clobazam could theoretically fill
39958143	2025	Case Report	Cureus	Perampanel reduced barbiturate dependency in a 13-year-old FIRES patient; underscores the unmet clinical need for oral weaning agents in FIRES and the absence of established options, which this repurposing inquiry aims to address

Note: Neither publication directly studies clobazam in FIRES. Both provide indirect support through demonstration of oral/enteral neuroactive agents as weaning strategies in the same condition.

New Zealand Market Information

Clobazam is not currently authorised or marketed in New Zealand (Medsafe). No product licences were found in the regulatory database query conducted on 2026-03-29.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for clobazam specifically in FIRES is absent — the two supporting publications concern other benzodiazepines and unrelated agents, with no clinical trials and no direct clobazam data in this indication. The mechanistic extrapolation (GABA-A PAM → super-refractory status epilepticus weaning) is pharmacologically coherent but remains unvalidated in the FIRES population.

To proceed, the following is needed:

Fill data gaps first: Obtain formal MOA data from DrugBank and retrieve the package insert (including warnings and contraindications) before any safety assessment can be initiated
Targeted literature search: Conduct a dedicated search for clobazam specifically in FIRES sub-acute phase or NORSE management — current search used broad FIRES terms and may have missed case-level reports
Design a research question: Formulate a prospective case series or international FIRES registry sub-study examining clobazam as an oral midazolam-weaning strategy, with pre-specified endpoints (days to wean, seizure recurrence rate, discharge ASM regimen)
Tolerance risk assessment: Evaluate benzodiazepine tolerance and withdrawal risk in the FIRES clinical context before escalating evidence stage; this is a known class-effect concern for long-term BZD use
Consider prioritising rank-6 indication: Among all ten TxGNN-predicted indications, childhood-onset epileptic encephalopathy (rank 6; primarily Lennox-Gastaut syndrome; Evidence Level L1, AAN Level A) represents a far more immediately actionable repurposing target — clobazam already holds FDA approval for LGS and a New Zealand regulatory submission pathway (Medsafe section 23 application) deserves higher priority in the near term
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.